Space42 secures $695.5m to launch next-gen UAE satellites
The financing represents a pivotal step in Space42's strategy to establish critical connectivity capabilities across multiple orbits. The facility, arranged by Crédit Agricole CIB, Santander CIB, Societe Generale, and Natixis and backed by Bpifrance Assurance Export, demonstrates the company's continued appeal to leading international banks and will fund the satellites scheduled for launch in 2027 and 2028. The facility provides Space42 with cost-effective, long-term financing aligned with its satellite development timeline, whilst strengthening the company's liquidity position to support future growth initiatives.
'The Al Yah 4 and Al Yah 5 programme is underpinned by a 17-year, $5.1bn government contract commencing in 2026 and advances our goal to become the trusted leader in secure connectivity by providing multi-path critical connectivity solutions,' said Andrew Cole, chief financial officer of Space42. 'This strategic pillar focuses on enhancing secure communication capabilities across defense and civil domains through multi-orbit satellite networks that ensure uninterrupted connectivity for mission-critical applications. The ECA financing structure optimises our cost of funding and provides increased financial flexibility to execute our growth agenda.'
Read:
Advanced satellite capabilities
Al Yah 4 and Al Yah 5 feature software-defined architecture with fully flexible payloads that can be reconfigured in orbit. This technology enables real-time optimisation of coverage, bandwidth, and frequency allocation to meet evolving operational requirements across the Middle East, Africa, Europe, and Asia.
The satellites will complement and eventually replace Al Yah 1 and Al Yah 2, launched in 2011 and 2012 respectively.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
13 minutes ago
- Zawya
UAE: Apex Investment records higher profits at $19.48mln in H1-25
Abu Dhabi – Apex Investment Company logged net profits after tax amounting to AED 71.59 million in the first half (H1) of 2025, compared to AED 23.01 million in H1-24. The ADX-listed firm posted revenues worth AED 399.86 million as of 30 June 2025, an annual plunge from AED 425.23 million, according to the financial results. Basic earnings per share (EPS) grew to AED 0.020 in H1-25 from AED 0.006 during the same period in 2024. Financials for Q2 In the second quarter (Q2) of 2025, the company's net profits hiked to AED 97.19 million from AED 18.74 million a year earlier, while the revenues shrank to AED 203.45 million from AED 229.91 million. The basic EPS stood at AED 0.027 in the three-month period that ended on 30 June 2025, up from AED 0.005 in Q2-24. As of 31 March 2025, Apex Investment turned to net losses valued at AED 25.59 million, against net profits worth AED 4.27 million in Q1-24. All Rights Reserved - Mubasher Info © 2005 - 2025 Provided by SyndiGate Media Inc. (
Zawya
13 minutes ago
- Zawya
Zain KSA sees 28% higher profits in H1-25; revenues hit $1.41bln
Riyadh – The net profits of Mobile Telecommunication Company Saudi Arabia (Zain KSA) hit SAR 220 million in the first half (H1) of 2025, an annual leap of 27.90% from SAR 172 million. The Saudi group generated revenues amounting to SAR 5.34 billion in H1-25, higher by 5.05% year-on-year (YoY) than SAR 5.08 billion, according to the financial statements. Earnings per share (EPS) reached SAR 0.24 as of 30 June 2025, up from SAR 0.19 in H1-24. Financials for Q2-25 In the second quarter (Q2) of 2025, Zain KSA achieved net profits valued at SAR 127 million, marking a 20.95% YoY jump from SAR 105 million in Q2-24. The revenues witnessed a 3.99% rise to SAR 2.65 billion in Q2-25, compared to SAR 2.55 billion a year earlier. Quarterly, the Q2-25 net profits surged by 36.55% from SAR 93 million in Q1-25, while revenues declined by 1.33% from SAR 2.69 billion. All Rights Reserved - Mubasher Info © 2005 - 2025 Provided by SyndiGate Media Inc. (
Zawya
43 minutes ago
- Zawya
Minapharm's majority shareholder Triquera raises capital through minority stake investment from Admaius Capital Partners
Cairo, Egypt - Admaius Capital Partners ('Admaius'), an Africa-focused private equity investor, and Triquera B.V. ('Triquera'), the majority shareholder in Minapharm Pharmaceuticals and Chemical Industries S.A.E. ('Minapharm'), a leading biopharmaceutical company in the Middle East and Africa and a global provider of proprietary technologies to leading biopharma players, today announced a strategic partnership following Admaius' investment in Triquera B.V. For over two decades, Minapharm has established a robust biopharmaceutical platform that combines world-class R&D with end-to-end manufacturing capabilities for complex genetically engineered therapeutic recombinant proteins and viral vectors as well as small molecules with advanced galenic formulations, operating across facilities in Cairo and Berlin. Today, Minapharm operates the largest biological drug substance and drug product facilities in the Middle East and Africa. Through its international subsidiaries, Minapharm licenses out proprietary technologies in the fields of monoclonal antibodies, vaccines, and cell and gene therapies. These technologies enable the development and production of advanced biologics that address critical unmet medical needs globally and have been incorporated into FDA-approved products, underscoring their clinical relevance and global impact. Together, Triquera and Admaius will focus on accelerating the development and production of complex genetically engineered therapies, while expanding access to high-quality, affordable recombinant proteins by investing in innovation and scaling distribution to better serve patients across underserved markets in Africa and the Middle East. In parallel, the partnership will pursue strategic acquisitions of global contract development and manufacturing organizations (CDMOs) to support Minapharm's growth in the biotech sector. This partnership reflects a shared commitment to advancing healthcare equity through innovation and aligns closely with Admaius' broader strategy of supporting mission-driven businesses and management teams in high-impact sectors across the African continent. Zilla Capital acted as the sole financial advisor to Triquera B.V. and the existing shareholders. Matouk Bassiouny served as legal counsel to Triquera B.V. and the existing shareholders. Admaius Capital Partners was advised by White and Case LLP as legal counsel and by Arthur D. Little as commercial advisor. Commenting on the investment: Dr. Wafik Bardissi, Chairman and CEO of Minapharm, said: "This partnership reflects the accelerating momentum of Minapharm's growth as we extend our leadership in biotherapeutics, cell and gene therapies, and proprietary platform technologies. With Admaius, we gain not only capital but a strategic partner whose insight, alignment, and ambition match our own. Together, we are advancing regional self-sufficiency and expanding the global reach of our innovations." Marlon Chigwende, Managing Partner of Admaius, said: 'This is a landmark transaction. The founding families have built a unique asset on the African and European continents that combines scale, growth and impact to fight cancer and other awful diseases. We are pleased to be able to partner with Triquera, Dr. Wafik and Dr. Shaheer and will help to internationalize and grow the business further.' Ahmed Rady, Managing Director of Admaius, said: 'At Admaius, we back exceptional management teams—and the team behind Minapharm is as impressive as the science, technology, and capabilities they've built across Cairo and Berlin. This partnership is about scaling a homegrown champion that combines cutting-edge global know-how with end-to-end manufacturing excellence. We're excited to support Minapharm in taking this next big step and look forward to working closely with the management team.' Dr. Shaheer Bardissi, Co-CEO of Minapharm, added: 'This strategic collaboration with Admaius will accelerate and scale Minapharm's vision of translating cutting-edge scientific innovation into affordable therapies, while advancing global scientific frontiers in immunotherapy as well as advanced therapy medicinal products, for the benefit of the broader biopharmaceutical industry.' Contacts For more information, please contact: Minapharm Christina Azmy cazmy@ (+2) (02) 24143170 Admaius Hannah Gilkes Phone number: +44 7515 958912
